FARETINA Study Confirms Faricimab Durability

An IRIS Registry analysis presented at ARVO 2026 shows stable vision, durability, and reduced treatment burden across more than 40,000 eyes over 2 years.

By: Ferhina Ali, MD

Retinal Physician May 7, 2026

Content Currently Unavailable

Ferhina S. Ali

Retina Specialist

Affiliations: New York Medical College and Westchester Medical Center

Specialties: Ophthalmology

Bio: Ferhina S. Ali, MD, is a retina specialist practicing in Westchester at New York Medical College and Westchester Medical Center. Her clinical and research focus includes retinal disease, including neovascular age-related macular degeneration.

Ferhina Ali

Retina specialist

Affiliations: New York Medical College and Westchester Medical Center

Specialties: Ophthalmology

Bio: Ferhina S. Ali, MD, is a retina specialist practicing in Westchester at New York Medical College and Westchester Medical Center. She presented 2-year data from the FARETINA study at ARVO 2026, reporting real-world outcomes with faricimab in neovascular age-related macular degeneration using the American Academy of Ophthalmology's IRIS Registry. Her recent work is focused on medical retina and real-world clinical outcomes in retinal disease, including treatment durability, visual outcomes, and treatment burden in patients with wet AMD. Through presentations and authorship in ophthalmic media, she has contributed to discussion of registry-based evidence evaluating faricimab use across large cohorts of treatment-naive and previously treated eyes.

PentaVision

Retinal Physician

FARETINA Study Confirms Faricimab Durability

Recommendations